KYNTRA BIO, INC. Cash and Cash Equivalents, Period Increase (Decrease)
KYNTRA BIO, INC. (KYNB) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$14.65 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-09
- KYNTRA BIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$14.65M.
- KYNTRA BIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $22.29M.
- KYNTRA BIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $361.10M, a 4487.09% increase year-over-year.
- KYNTRA BIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $119.68M, a 142.01% increase year-over-year.
- KYNTRA BIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $499.88M, a 2343.43% increase from fiscal 2016.
- KYNTRA BIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $20.46M.
- KYNTRA BIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$12.13M, a 113.61% decline from fiscal 2014.
- KYNTRA BIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $89.12M, a 137.92% increase from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | -$14.65M 10-Q · filed 2018-05-09 | $7.63M derived: sum of 2 quarters · filed 2018-05-09 | $368.73M derived: sum of 3 quarters · filed 2018-05-09 | $488.41M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-12-31 | $22.29M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $383.38M derived: sum of 2 quarters · filed 2018-02-27 | $503.06M derived: sum of 3 quarters · filed 2018-02-27 | $499.88M 10-K · filed 2018-02-27 | |
| 2017-09-30 | $361.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $480.77M derived: sum of 2 quarters · filed 2017-11-08 | $477.59M 10-Q · filed 2017-11-08 | $453.09M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-06-30 | $119.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $116.50M 10-Q · filed 2017-08-07 | $91.99M derived: sum of 3 quarters · filed 2018-05-09 | $99.87M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-03-31 | -$3.18M 10-Q · filed 2018-05-09 | -$27.68M derived: sum of 2 quarters · filed 2018-05-09 | -$19.81M derived: sum of 3 quarters · filed 2018-05-09 | $29.64M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2016-12-31 | -$24.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$16.63M derived: sum of 2 quarters · filed 2018-02-27 | $32.82M derived: sum of 3 quarters · filed 2018-02-27 | $20.46M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $7.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $57.32M derived: sum of 2 quarters · filed 2017-11-08 | $44.96M 10-Q · filed 2017-11-08 | -$1.90M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $49.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $37.09M 10-Q · filed 2017-08-07 | -$9.77M derived: sum of 3 quarters · filed 2018-02-27 | -$46.13M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | -$12.37M 10-Q · filed 2017-05-09 | -$59.23M derived: sum of 2 quarters · filed 2018-02-27 | -$95.58M derived: sum of 3 quarters · filed 2018-02-27 | $12.59M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2015-12-31 | -$46.86M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$83.21M derived: sum of 2 quarters · filed 2018-02-27 | $24.95M derived: sum of 3 quarters · filed 2018-02-27 | -$12.13M 10-K · filed 2018-02-27 | |
| 2015-09-30 | -$36.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $71.81M derived: sum of 2 quarters · filed 2016-11-08 | $34.73M 10-Q · filed 2016-11-08 | $43.20M 10-Q · filed 2015-11-12 | $46.30M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $108.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $71.08M 10-Q · filed 2016-08-08 | $82.65M derived: sum of 3 quarters · filed 2017-03-01 | $53.87M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | -$37.09M 10-Q · filed 2016-05-09 | -$25.52M derived: sum of 2 quarters · filed 2017-03-01 | -$54.29M derived: sum of 3 quarters · filed 2017-03-01 | $55.42M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $11.57M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$17.21M derived: sum of 2 quarters · filed 2017-03-01 | $92.50M derived: sum of 3 quarters · filed 2017-03-01 | $89.12M 10-K · filed 2017-03-01 | |
| 2014-09-30 | -$28.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $80.94M derived: sum of 2 quarters · filed 2015-11-12 | $77.56M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $109.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $106.33M 10-Q · filed 2015-08-13 | |||
| 2014-03-31 | -$3.38M 10-Q · filed 2015-05-12 | ||||
| 2013-12-31 | $37.46M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |